Association of Maternal Eligibility for the Deferred Action for Childhood Arrivals Program With Citizen Children's Participation in the Women, Infants, and Children Program
Nearly 7% of children living in the United States, the vast majority of whom are US citizens, have at least 1 undocumented immigrant parent. 1 These children face several disadvantages, culminating in reduced lifetime socioeconomic mobility and reduced well-being. 1 One mechanism underlying these adverse consequences could be failure to receive critical public benefits despite meeting eligibility criteria because undocumented parents may be less likely to apply for these services on their child's behalf if they fear being discovered by immigration authorities. 2, 3 Policies that bring undocumented parents "out of the shadows," such as the 2012 Deferred Action for Childhood Arrivals (DACA) program, may have positive spillover effects for their children by improving uptake of public benefits. We examined the association of parental DACA eligibility with children's participation in the Women, Infants, and Children (WIC) program, a benefit that has been shown to improve child health and socioeconomic outcomes. 4 Methods | We used data from the 2010-2015 National Health Interview Surveys (NHIS). Our sample consisted of US citizen children who were 5 years of age or younger (reflecting WIC age eligibility criteria) and whose mothers were Hispanic and not US citizens. The latter criterion follows earlier work that noted that a large percentage (>60%) of self-reported noncitizens are undocumented. 5 In addition, we further restricted the sample to children whose mothers had lived in the United States for at least 5 years. We also restricted our sample to children of mothers who were 19 years of age or older and had received at least a high school diploma or General Educational Development certificate, to hold fixed 2 key DACA eligibility criteria. 5 This study was acknowledged as exempt, non-human subjects research by the Johns Hopkins School of Medicine Institutional Review Board. Our main outcome was whether the child was enrolled in WIC in the previous calendar year (the period queried by the NHIS). Our main exposure-whether the mother met DACA eligibility criteria-was defined on the basis of the mother's age at immigration (≤16 years) and age at DACA implementation (≤31 years at policy implementation). 5 We estimated a difference-in-difference model that compared changes in WIC enrollment among children whose mothers met the 2 DACA age eligibility criteria before (survey years, 2010-2012) vs after (survey years, 2014-2015) policy introduction with changes among children whose mothers did not meet these criteria. (Survey year 2013 was excluded because it corresponded to WIC participation in the year DACA was implemented). We adjusted for sociodemographic characteristics of both the child and mother. 6 All descriptive statistics and analyses were performed using NHIS sample weights.
Results | Our final sample consisted of 1911 children 5 years or younger, of whom 33.8% had a mother who likely met DACA eligibility criteria (Table 1) . Overall, 43.1% children participated in the WIC program during the study period.
A mother's DACA eligibility was associated with a 12.3% (95% CI, 0.7%-23.9%) higher likelihood that her child participated in WIC ( Table 2) . Among children whose families met broad WIC income eligibility criteria (family income <185% of the federal poverty level or Medicaid receipt), we found similar estimates (β coefficient, 13.5%; 95% CI, 0.81%-26.3%). We did not find an association among children with noncitizen mothers who likely would not have met DACA eligibility criteria on the basis of educational attainment (falsification test).
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Discussion | Maternal eligibility for the DACA program was associated with increased participation in WIC by their citizen children. These results highlight the potential for multigenerational spillover effects of immigration policy.
A limitation of our analysis is that we were unable to explicitly identify undocumented parents or make strict determinations of DACA eligibility. However, these limitations are true of all nationally representative data sets and likely will result in underestimates of program effects.
5 A second limita- 
COMMENT & RESPONSE

Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy
To the Editor Prasad's editorial is disappointing, suggesting that nusinersen was given too broad a label and its efficacy is "marginal."
1 He infers insurance companies should decline coverage for milder types of spinal muscular atrophy (SMA). Delegating medical decision making to a company seems ethically unsound.
Prasad states "the randomized data submitted to the FDA [US Food and Drug Administration] supporting the benefit of nusinersen is, to date, for only one particular subgroup of the disease (SMA subtype 1). The broader FDA data approval was made for all subtypes based on uncontrolled data." 1 This is not true. There were 3 clinical trials (CS3B, CS4, and SM202) and multiple uncontrolled trials reviewed. Statistical analysis could only be performed for CS3B, but topline data were reviewed for CS4 (later-onset SMA). This is well-documented in multiple aspects of the FDA review, including the unreferenced clinical efficacy review.
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CS3B is a study of infantile-onset SMA, not SMA type 1. Inclusion criteria were biased toward SMA type 1, but SMA exists on a spectrum with typing based on maximum motor milestones. Spinal muscular atrophy is not like cancer, where myriad factors are thought to play a major role in modifying disease pathogenesis. Ninety-five percent of all patients, regardless of type, carry the same SMN1 deletions. The predominant difference between SMA types is SMN2 copy numbers. Those with fewer SMN2 copies have more severe disease. Nusinersen acts on SMN2 transcripts. Common sense predicts an equal or greater drug effect will be seen in SMA types 2 through 4. Prasad recommends "caution in extrapolating benefits shown in severe disease settings to more indolent settings." 1 I generally agree, but when subspecialists and the FDA 3 provide rational arguments to the contrary, perhaps he should listen. The information from the clinical trials will only address SMA types 1 and 2, accounting for 87% of SMA. 4 Results are also pending for a presymptomatic trial that mimics newborn screening, a logical follow-up study. The sponsor should not be belabored for not crafting appropriate trials. The only areas that I, as a specialist in the field, bemoan are the cost of the drug and time it takes to publish clinical trial data in peer-reviewed journals. This is the best way to allow readers to come to their own opinion about the efficacy of nusinersen.
In Reply Richardson makes 4 errors. First, I note insurers might choose to decline coverage of nusinersen where it does not have randomized data supporting its use. 1 An insurer using controlled data to make coverage decisions for a drug that costs $750 000 in the first year and offers a marginal benefit has become a tragic reality of 2018. Because manufacturers price medications unconscionably, patients, payers, and society are put in the impossible position of choosing between costly, marginal drugs or the health needs of many children. Second, data from CS4, the CHERISH study, are now published, but at the time of US Food and Drug Administration (FDA) approval it was specifically noted in the medical review as "not submitted as part of this NDA [new drug application] and therefore could not be reviewed." 2 SM202
was ongoing at the time of FDA approval. 2 The FDA makes this clear: "the sham-procedure controlled study CS3B is the one adequate and well-controlled efficacy study that can support approval of nusinersen." 2 Uncontrolled data offer limited value for judging the efficacy of this drug. If uncontrolled data were informative, sham control trials would not have been performed. The CHERISH study now confirms the effect size of ENDEAR. Nusinersen improves the Hammersmith Functional Motor Scale-Expanded 3.9 points from baseline and 4.9 points vs sham control (final analysis). 3 Given that the mean
Hammersmith Functional Motor Scale-Expanded score on entry was 22.4 in the Nusinersen group and 19.9 in the sham group (the scale ranges from 0 to 66), although this is a positive trial, nusinersen does not represent a cure, offers a marginal effect size, and leaves room for more effective agents.
